Evidence map›Paper›PMID 39686634›Full record

ArticleCurrent medicinal chemistry2026

Anticancer and Cyclooxygenase Inhibitory Activity of Benzylidene Derivatives of Fenobam and its Thio Analogues.

Wafa Hourani, Pran Kishore Deb, Maysa Alhawamdeh, Nizar Al-Shari, Pobitra Borah, Lina A Dahabiyeh, Abdulmuttaleb Yousef Jaber, Nefisath Pandikatte, Shashiprabha Sudhakar, Jagadeesh Prasad Dasappa and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wafa HouraniDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, 19392, Jordan.
Pran Kishore DebDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology (BIT), Mesra, Ranchi, 835215, India.ORCID 0000-0002-8650-2874
Maysa AlhawamdehDepartment of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Mutah University, Al-Karak, 61710, Jordan.ORCID 0000-0001-9215-7643
Nizar Al-ShariDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.ORCID 0000-0002-1599-5704
Pobitra BorahDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, 208016, Uttar Pradesh, India.
Lina A DahabiyehDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Queen Rania St, Amman, 11942, Jordan.
Abdulmuttaleb Yousef JaberDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, 19392, Jordan.
Nefisath PandikattePost Graduate Department of Chemistry, Sri Dharmasthala Manjunatheshwara College (Autonomous), Ujire, 574240, India.
Shashiprabha SudhakarPost Graduate Department of Chemistry, Sri Dharmasthala Manjunatheshwara College (Autonomous), Ujire, 574240, India.
Jagadeesh Prasad DasappaDepartment of PG Studies and Research in Chemistry, Mangalore University, Mangalagangothri, 574199, India.
Katharigatta N VenugopalaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.ORCID 0000-0003-0680-1549

Funding

BIT Mesra, Ranchi BIT/DRIE/SMS/2024-25/1877Deanship of Scientific Research and Graduate Studies, Philadelphia University 100/34/541/2022Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia KFU241977
6 · The paper itself

Abstract

introductionA series of benzylidene derivatives of fenobam and its thio analogues (1-22) have been evaluated for their cytotoxicity against breast cancer (MCF-7, MDA-MB-231), ovarian cancer (A2780, SKOV-3) and cervical cancer (HELA) cell lines.

methodsThese compounds (1-22) exhibited 72-83% inhibition of Erk activity against the ovarian cancer cell line (A2780). Compounds 3 and 20 showed the highest DNA damage effect in comet assay against the A2780 cancer cell line as compared to the other tested analogues (4, 8, 11, 12, and 13) by using % Tail DNA and OTM. Compounds 3, 4, and 11 showed significant activities and selectivity towards COX-2 with 78%, 97%, and 89% inhibition, as compared to 17%, 57%, and 26% inhibition against COX-1 isoenzyme, respectively.

resultsInterestingly, molecular docking scores were also in very good agreement with the experimental results regarding discriminating the selectivity index of the tested compounds against COX-1 & COX-2 enzymes. Further molecular dynamics (MD) simulation study revealed that the most selective compound, 13, binds with the COX-2 enzyme in a similar fashion to that of Rofecoxib, which was further supported by their MD-based free binding energies (MM-GBSA) of -49.76 ± 4.27 kcal/mol, and -44.84 ±3.78 kcal/mol, respectively.

conclusionMoreover,

Indexed as

Antineoplastic AgentsBenzylidene CompoundsCyclooxygenase InhibitorsCell Line, TumorCell ProliferationCyclooxygenase 1Cyclooxygenase 2Drug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBenzylidene CompoundsCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsBenzylidene derivativescancerCOMET assayCOX 1 inhibitionCOX 2 inhibitionErk analysis.

Identifiers

PMID39686634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.